Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Medy Tox Inc    086900   KR7086900008

MEDY TOX INC

(086900)
My previous session
Most popular
  Report  
No quotes available
-- KRW   --.--%
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Medy Tox : US phase 3 studies imminent for Medytoxs liquid BTX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/30/2018 | 05:57am EDT

Medytox has sent out a pilot batch of its liquid-type botulinum toxin Innotox to its US partner Allergan to initiate the long-awaited phase 3 clinical trials of the drug candidate that treats frown lines, analysts said on May 29.

Allergan said it would start the clinical program if Medytox supplies the Innotox samples in the second quarter. Although Medytox has not officially confirmed whether it has sent the samples to Allergan, related data shows it did so, said Kim Mi-hyun, an analyst at Eugene Investment & Securities.

Botox maker Allergan recently decided to begin the final-stage clinical studies in the fourth quarter of this year on Innotox, also known as MT10109L that the US company bought a global license from Medytox in 2013.

According to data from the Korea Customs Service, Medytox exported some US$520,000 worth of Innotox to, to Allergans headquarters in Dublin, Ireland. Given that any botulinum toxin produced by Korean firm has not been approved for export to the country, analysts assume that the exported product are Innotox samples to be used for clinical trials.

The company seems to have shipped the samples from its plant No.2, as this facility is exclusively dedicated to Allergan products, said Song Eun-jeong, an analyst at Nomura Securities.

It appears that Medytoxs plans to enter the US market is being delayed, as Allergan had initially planned for the clinical trials in 2015. The latest setback occurred in 2017 when the trials faced another delay due to scale-up production issues with Medytox, following Allergans announcement in its 2016 second-quarter earnings report that it would begin the phase 3 trials of Innotox in early 2017.

(c) APS 2018. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDY TOX INC
2018MEDY TOX : US phase 3 studies imminent for Medytoxs liquid BTX
AQ
More news
Financials (KRW)
Sales 2019 237 B
EBIT 2019 106 B
Net income 2019 86,7 B
Finance 2019 19,7 B
Yield 2019 0,46%
P/E ratio 2019 36,50
P/E ratio 2020 28,98
EV / Sales 2019 13,2x
EV / Sales 2020 11,0x
Capitalization 3 148 B
Chart MEDY TOX INC
Duration : Period :
Medy Tox Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 693 253  KRW
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Hyun-Ho Jeong Chief Executive Officer & Director
Gi-Hyuk Yang Director & Head-Research
Tae-Cheon Jeong Outside Director
Seung-Beom Park Director & Head-Production
Young-Ik Cheon Auditor
Sector and Competitors
1st jan.Capitalization (M$)
MEDY TOX INC2 786
CSL LIMITED4.90%62 615
BIOGEN-24.60%44 629
ALEXION PHARMACEUTICALS37.85%29 992
SAMSUNG BIOLOGICS CO LTD--.--%20 407
GRIFOLS3.28%16 488